{"id":46123,"date":"2022-07-13T14:01:54","date_gmt":"2022-07-13T12:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/"},"modified":"2022-07-13T14:01:54","modified_gmt":"2022-07-13T12:01:54","slug":"synchron-appoints-kurt-haggstrom-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/","title":{"rendered":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Synchron<\/a>, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents.\n<\/p>\n

<\/a><\/p>\n

\n\u201c<\/b>I am honored and excited to join the Synchron team and be part of this amazing journey to help the millions of people worldwide who suffer from paralysis,\u201d said Kurt Haggstrom, Chief Commercial Officer, Synchron. \u201cThroughout the past 20+ years, I have pursued my passion within the medical technology industry to help improve the lives of patients all around the world. I am eager to bring my experience to Synchron to help support its mission of developing an endovascular implant that can transfer information from every corner of the brain at scale.\u201d\n<\/p>\n

\nAt Synchron, Haggstrom will lead the commercial organization, including product, marketing and reimbursement.\n<\/p>\n

\nHaggstrom most recently served as Vice President of Global Product and Strategy Marketing at Cordis, a manufacturer of interventional cardiovascular technology. Previously, Haggstrom served as the Global Director of Marketing, Neurovascular at Medtronic, a leading medical equipment manufacturer, where he worked for 18 years. During his time at Medtronic, Haggstrom worked in several roles in product management and marketing, including playing a critical role in the development and commercial launch of the disruptive pipeline embolization device.\n<\/p>\n

\n\u201cWe are thrilled to have Kurt join the team. Kurt will bring world-class commercial leadership to ensure we have designed the product and clinical trials in readiness for launch of the first commercial implantable BCI into the U.S. market,\u201d said Tom Oxley, CEO, Synchron. \u201cKurt joins us at a crucial moment in our development, on the heels of successful clinical results in our Australia trial, and commencement of our U.S. trial.\u201d\n<\/p>\n

\nHaggstrom\u2019s hiring follows Synchron\u2019s recent enrollment<\/a> of the first-ever BCI implant in the U.S. at Mount Sinai hospital in New York. Once complete, the procedure will mark a milestone in the BCI community when the first U.S. patient receives the Stentrode BCI.\n<\/p>\n

\n\u200b\u200bAbout the Stentrode\u2122<\/b>\n<\/p>\n

\nSynchron\u2019s flagship technology, the Stentrode, is an endovascular brain implant designed to enable patients to wirelessly control digital devices through thought and improve functional independence. Synchron\u2019s foundational technology, a motor neuroprosthesis (MNP), or motor BCI, is implanted via the jugular vein using neurointerventional techniques commonly used to treat stroke, and does not require drilling into the skull or open brain surgery. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.\n<\/p>\n

\nAbout Synchron, Inc.<\/b>\n<\/p>\n

\nSynchron, an endovascular brain interface company, is a leader in implantable neural interface technology. The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable neuromodulation therapy. Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson\u2019s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City, with offices in Silicon Valley, California and R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com<\/a>. Follow us on Twitter @synchroninc<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKimberly Ha
\n
Synchron
\n
kha@synchron.com<\/a><\/p>\n

Tyler Hubin
\n
Moxie Communications Group
\n
synchron@moxiegrouppr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. \u201cI am honored and excited to join the Synchron team and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46123","6":"format-standard","7":"category-industry"},"yoast_head":"\nSynchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. \u201cI am honored and excited to join the Synchron team and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T12:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer\",\"datePublished\":\"2022-07-13T12:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/\"},\"wordCount\":557,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005190\\\/en\\\/1511899\\\/21\\\/synchron-new-logo-featured.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/\",\"name\":\"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005190\\\/en\\\/1511899\\\/21\\\/synchron-new-logo-featured.jpg\",\"datePublished\":\"2022-07-13T12:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005190\\\/en\\\/1511899\\\/21\\\/synchron-new-logo-featured.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005190\\\/en\\\/1511899\\\/21\\\/synchron-new-logo-featured.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. \u201cI am honored and excited to join the Synchron team and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T12:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer","datePublished":"2022-07-13T12:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/"},"wordCount":557,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/","url":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/","name":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg","datePublished":"2022-07-13T12:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220713005190\/en\/1511899\/21\/synchron-new-logo-featured.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synchron-appoints-kurt-haggstrom-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Synchron Appoints Kurt Haggstrom as Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46123"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46123\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}